메뉴 건너뛰기




Volumn 37, Issue 7, 2016, Pages 930-940

Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice

Author keywords

EGFR; erlotinib; non small cell lung cancer; PK PD model; simulation; sunitinib; synergistic effect; VEGFR

Indexed keywords

ERLOTINIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 84977117553     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2016.55     Document Type: Article
Times cited : (22)

References (28)
  • 1
    • 84907049059 scopus 로고    scopus 로고
    • Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
    • Lee CC, Shiao HY, Wang WC, Hsieh HP. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2014; 23: 1333-48.
    • (2014) Expert Opin Investig Drugs , vol.23 , pp. 1333-1348
    • Lee, C.C.1    Shiao, H.Y.2    Wang, W.C.3    Hsieh, H.P.4
  • 3
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    • Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
    • (2004) J Clin Oncol , vol.22 , pp. 3238-3247
    • Perez-Soler, R.1    Chachoua, A.2    Hammond, L.A.3    Rowinsky, E.K.4    Huberman, M.5    Karp, D.6
  • 4
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
    • (2003) Clin Cancer Res , vol.9 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3    Louie, S.G.4    Christensen, J.G.5    Li, G.6
  • 5
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-8.
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 6
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 7
    • 84871992219 scopus 로고    scopus 로고
    • Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients
    • Lin L, Bivona TG. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012; 2012: 817297.
    • (2012) Chemother Res Pract , vol.2012 , pp. 817297
    • Lin, L.1    Bivona, T.G.2
  • 8
    • 51149086367 scopus 로고    scopus 로고
    • Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications
    • Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008; 5: 521-30.
    • (2008) Nat Clin Pract Oncol , vol.5 , pp. 521-530
    • Tortora, G.1    Ciardiello, F.2    Gasparini, G.3
  • 9
    • 66149163097 scopus 로고    scopus 로고
    • Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    • Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15: 3484-94.
    • (2009) Clin Cancer Res , vol.15 , pp. 3484-3494
    • Naumov, G.N.1    Nilsson, M.B.2    Cascone, T.3    Briggs, A.4    Straume, O.5    Akslen, L.A.6
  • 10
    • 80054122779 scopus 로고    scopus 로고
    • EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    • Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N, et al. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 2011; 17: 6522-30.
    • (2011) Clin Cancer Res , vol.17 , pp. 6522-6530
    • Poindessous, V.1    Ouaret, D.2    El Ouadrani, K.3    Battistella, A.4    Megalophonos, V.F.5    Kamsu-Kom, N.6
  • 11
    • 84863936062 scopus 로고    scopus 로고
    • Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
    • Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070-8.
    • (2012) J Clin Oncol , vol.30 , pp. 2070-2078
    • Scagliotti, G.V.1    Krzakowski, M.2    Szczesna, A.3    Strausz, J.4    Makhson, A.5    Reck, M.6
  • 12
    • 84877040641 scopus 로고    scopus 로고
    • Modeling NSCLC progression: Recent advances and opportunities available
    • Suleiman AA, Nogova L, Fuhr U. Modeling NSCLC progression: recent advances and opportunities available. AAPS J 2013; 15: 542-50.
    • (2013) AAPS J , vol.15 , pp. 542-550
    • Suleiman, A.A.1    Nogova, L.2    Fuhr, U.3
  • 13
    • 48249084994 scopus 로고    scopus 로고
    • A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients
    • Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 4213-8.
    • (2008) Clin Cancer Res , vol.14 , pp. 4213-4218
    • Tham, L.S.1    Wang, L.2    Soo, R.A.3    Lee, S.C.4    Lee, H.S.5    Yong, W.P.6
  • 14
    • 84876469913 scopus 로고    scopus 로고
    • Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine
    • Li M, Li H, Cheng X, Wang X, Li L, Zhou T, et al. Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. Pharm Res 2013; 30: 1400-8.
    • (2013) Pharm Res , vol.30 , pp. 1400-1408
    • Li, M.1    Li, H.2    Cheng, X.3    Wang, X.4    Li, L.5    Zhou, T.6
  • 15
    • 67651171223 scopus 로고    scopus 로고
    • Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development
    • Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009; 86: 167-74.
    • (2009) Clin Pharmacol Ther , vol.86 , pp. 167-174
    • Wang, Y.1    Sung, C.2    Dartois, C.3    Ramchandani, R.4    Booth, B.P.5    Rock, E.6
  • 16
    • 84865285731 scopus 로고    scopus 로고
    • Sensitive LCMS/MS method to determine the concentrations of erlotinib and its active metabolite OSI420 in BALB/c nude mice plasma simultaneously and its application to a pharmacokinetic study
    • Li M, Wu Q, Li H, Ning M, Chen Y, Li L, et al. Sensitive LCMS/MS method to determine the concentrations of erlotinib and its active metabolite OSI420 in BALB/c nude mice plasma simultaneously and its application to a pharmacokinetic study. J Chin Pharm Sci 2012; 21: 296-303.
    • (2012) J Chin Pharm Sci , vol.21 , pp. 296-303
    • Li, M.1    Wu, Q.2    Li, H.3    Ning, M.4    Chen, Y.5    Li, L.6
  • 17
    • 84946155144 scopus 로고    scopus 로고
    • Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib (SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study
    • Li J, Li J, Wang S, Yuan Y, Su Q, Lu W, et al. Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib (SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chin Pharm Sci 2015; 24: 217-24.
    • (2015) J Chin Pharm Sci , vol.24 , pp. 217-224
    • Li, J.1    Li, J.2    Wang, S.3    Yuan, Y.4    Su, Q.5    Lu, W.6
  • 18
    • 77955986074 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941
    • Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38: 1436-42.
    • (2010) Drug Metab Dispos , vol.38 , pp. 1436-1442
    • Salphati, L.1    Wong, H.2    Belvin, M.3    Bradford, D.4    Edgar, K.A.5    Prior, W.W.6
  • 19
    • 0842282616 scopus 로고    scopus 로고
    • Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
    • Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101.
    • (2004) Cancer Res , vol.64 , pp. 1094-1101
    • Simeoni, M.1    Magni, P.2    Cammia, C.3    De Nicolao, G.4    Croci, V.5    Pesenti, E.6
  • 20
    • 67349159357 scopus 로고    scopus 로고
    • Modeling of tumor growth and anticancer effects of combination therapy
    • Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 2009; 36: 179-97.
    • (2009) J Pharmacokinet Pharmacodyn , vol.36 , pp. 179-197
    • Koch, G.1    Walz, A.2    Lahu, G.3    Schropp, J.4
  • 21
  • 22
    • 84865690782 scopus 로고    scopus 로고
    • Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study
    • Blumenschein GR Jr, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, et al. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 2012; 7: 1406-16.
    • (2012) J Thorac Oncol , vol.7 , pp. 1406-1416
    • Blumenschein, G.R.1    Ciuleanu, T.2    Robert, F.3    Groen, H.J.4    Usari, T.5    Ruiz-Garcia, A.6
  • 23
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
    • (2006) J Clin Oncol , vol.24 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3    Robert, C.4    Lozahic, S.5    Lassau, N.6
  • 24
    • 68149137164 scopus 로고    scopus 로고
    • Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species
    • Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009; 64: 691-706.
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 691-706
    • Haznedar, J.O.1    Patyna, S.2    Bello, C.L.3    Peng, G.W.4    Speed, W.5    Yu, X.6
  • 25
    • 0015071439 scopus 로고
    • Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents
    • Jusko WJ. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 1971; 60: 892-5.
    • (1971) J Pharm Sci , vol.60 , pp. 892-895
    • Jusko, W.J.1
  • 26
    • 34748854885 scopus 로고    scopus 로고
    • Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
    • Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26.
    • (2007) J Pharmacokinet Pharmacodyn , vol.34 , pp. 711-726
    • Savic, R.M.1    Jonker, D.M.2    Kerbusch, T.3    Karlsson, M.O.4
  • 27
    • 34547842118 scopus 로고    scopus 로고
    • Predicting the active doses in humans from animal studies: A novel approach in oncology
    • Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 2007; 43: 1862-8.
    • (2007) Eur J Cancer , vol.43 , pp. 1862-1868
    • Rocchetti, M.1    Simeoni, M.2    Pesenti, E.3    De Nicolao, G.4    Poggesi, I.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.